Myostatin Inhibitors vs. Traditional Anabolics: A Comparative Analysis

How the Two Approaches Differ

Most lifters already understand how traditional anabolics work. More testosterone (or a synthetic androgen) means more binding to the androgen receptor (AR) and more muscle protein synthesis. A common shorthand is that AAS press the gas pedal. The effect is dose-dependent and well studied: in a 1996 trial in the New England Journal of Medicine, 43 healthy men given 600 mg of testosterone enanthate weekly for 10 weeks gained more fat-free mass and muscle size than men on placebo, with the largest increases when testosterone was combined with strength training. Decades of use have also made the downsides well known.

Myostatin inhibitors work differently. Rather than pushing growth harder, they take away one of the signals that normally limits it, which is closer to releasing a brake. These compounds interfere with myostatin, a protein that tells muscle to stop growing. You're not stimulating growth directly; you're removing a restraint on it. Which approach does more, and at what cost, depends on which compounds and which evidence you look at.

Mechanism: Apples and Oranges for Muscle Growth

The two classes act on separate signaling pathways.

Traditional Anabolics: The Androgen Receptor Pathway

This is the classic pathway for muscle hypertrophy. Anabolic-androgenic steroids (AAS) like testosterone or trenbolone are lipids that pass through the cell membrane and bind to the androgen receptor in the cytoplasm. This newly formed complex then moves into the cell's nucleus, where it acts as a transcription factor: it turns on the genes responsible for building muscle proteins. This leads to increased nitrogen retention, a large spike in muscle protein synthesis, and enhanced recovery. It's an upstream, direct command to build more muscle.

Myostatin Inhibitors: The Activin Receptor Pathway

Myostatin inhibitors don't act on the androgen receptor at all. Their main target is a single protein: myostatin. Myostatin is your body's genetic handbrake on muscle growth. It circulates in your blood and binds to the Activin type IIB receptor (ActRIIB) on muscle cells, which triggers a signaling cascade that actively blocks growth. It's a 'stop' signal.

Peptides like follistatin (the FST-344 form is the one sold on the research market) or the experimental drug ACE-031 work by acting as decoys. They bind to myostatin in the bloodstream before it can reach its receptor, so the 'stop' signal never arrives. Neither is fully selective, though. ACE-031 is a soluble form of ActRIIB that also soaks up related proteins, and follistatin binds activin, a hormone that helps drive FSH release from the pituitary. Our myostatin inhibitors overview walks through the specific proteins involved.

That difference in mechanism explains much of why the results, and the risks, don't line up with AAS.

What Human Trials Show as of October 2026

Blocking the myostatin pathway is no longer untested in people, although none of the human data involve the products sold to lifters. As of October 2026:

• Apitegromab (Isembyld) became the first FDA-approved myostatin-targeted drug on September 11, 2026. It's approved for spinal muscular atrophy (SMA) in patients aged 2 and older who are already on an SMN2-targeted treatment, and it's given by IV infusion every four weeks. In the 52-week trial, 34.2% of children aged 2 to 12 on the 10 mg/kg dose showed a clinically meaningful motor improvement, against 13.5% on placebo. The FDA notes an increased risk of fractures and says the drug may affect reproductive function.
• BELIEVE, a Phase 2 trial of bimagrumab (an antibody against type II activin receptors) in 507 adults with obesity, was published in Nature Medicine in 2026. According to a summary from Pennington Biomedical, participants on semaglutide alone lost 15.7% of body weight, with 71.8% of that loss from fat. On the combination they lost 22.1%, with 92.8% from fat and lean mass largely preserved.
• COURAGE, Regeneron's Phase 2 trial of the myostatin antibody trevogrumab added to semaglutide, reported in October 2026. According to MedPath's summary, lean mass fell 7.3% at 52 weeks on semaglutide alone, versus 5.8% with 25 mg and 4.2% with 75 mg of trevogrumab. Trevogrumab didn't add weight loss. An arm that combined higher doses with the activin A antibody garetosmab had two deaths and more adverse events, and Regeneron dropped that combination.

Earlier, a single-dose study of ACE-031 in 48 healthy postmenopausal women found a 3.3% rise in lean mass at day 29 in the top-dose group. These trials show that blocking the pathway can preserve or add lean mass in humans. They don't show what happens in healthy, trained lifters, and they studied very different populations from the AAS trials, so a direct comparison doesn't hold. Our comparison of myostatin inhibitors and anabolics by results goes through those numbers side by side.

How the Muscle Gain Differs

The two classes are often said to produce a different look, but most of that idea comes from anecdote and animal data.

AAS-induced growth is primarily hypertrophy: making existing muscle fibers bigger. At higher doses, users commonly describe water retention and a 'full' or 'pumped' look, especially with compounds that convert to estrogen. That adds size and scale weight but can soften definition.

Myostatin inhibition looks different in animals. The classic example is the Belgian Blue cattle, which have a natural mutation in their myostatin gene. Myostatin knockout mice have both more muscle fibers (a phenomenon called hyperplasia) and larger ones. Hyperplasia in adult humans is still debated; the human trials above measured lean mass and muscle volume, not fiber number. Some bodybuilders who have used research-market follistatin describe a 'grainy' or 'denser' look without much change on the scale. We couldn't find any study that measured muscle density or water content in people using these products, and since what's in those vials is unverified, the reports are hard to interpret.

Side Effect Profiles

This is where the comparison matters most. With decades of use, the side effects of AAS are well documented. They are significant, but they are largely predictable. Myostatin inhibitors have far less human safety data, and nearly all of it comes from disease and obesity trials.

The table shows a trade rather than an upgrade. Myostatin inhibitors avoid the androgenic and estrogenic side effects of AAS but bring a newer set of risks that are harder to predict. Nobody anticipated the bleeding problems that stopped the ACE-031 trial, and the fracture signal with apitegromab only showed up in a controlled trial. Our ACE-031 overview covers what that trial found.

Stacking: What Users Report

These aren't interchangeable, and in bodybuilding communities no one describes swapping a testosterone base for follistatin.

On bodybuilding forums, AAS are usually described as the base of a growth phase. Follistatin and other myostatin-pathway products come up as short add-ons for experienced users who feel they've plateaued on AAS alone. The reasoning users give is that the two act on independent pathways, so combining them should add up. That's plausible on paper, but no one has tested the combination in people.

User posts often describe adding follistatin-344 at around 100 mcg per day for 2-4 weeks during an AAS cycle. That figure comes from community reports, not from any trial. We found no published human data for injected research-market follistatin protein at any dose. The human follistatin studies used gene therapy instead: in a small 2015 Becker muscular dystrophy trial, six patients received a virus carrying the follistatin gene by direct injection into the thigh muscles. Product quality adds another unknown, since vials sold as follistatin or 'ACE-031' aren't independently verified, and the real ACE-031 program was dropped in 2013. For tested athletes, WADA's 2026 Prohibited List names both follistatin and ACE-031 under S4.3 (agents preventing activin receptor IIB activation), prohibited at all times.

What We Still Don't Know

The approved and late-stage myostatin-pathway drugs are antibodies given by infusion or injection under medical supervision, and none is approved for building muscle. Whether preserved lean mass in the obesity trials translates into better strength or function is still debated, because function endpoints were limited. For research-market follistatin, there are no human data on dose, safety or effect, and no reliable way to know what a vial contains. Myostatin inhibitors aren't a safer alternative to steroids so much as a less-studied one, and the human trials that would answer that question in healthy adults haven't been run.

Comparison table